SCHEMBL5272201

SCHEMBL5272201

CCCN(CCCOc1ccccc1C(=O)O)c1nc2ccccc2o1

nearest known ligand 0.51

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 20/20 0.51
PPARD Q03181 17/20 0.51
PPARG P37231 17/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5277585 0.97 PPARA (0.52) PPARAPPARDPPARG
SCHEMBL5579724 0.96 PPARA (0.52) PPARAPPARDPPARG
SCHEMBL5274279 0.95 PPARG (0.49) PPARAPPARDPPARG
SCHEMBL5273658 0.94 PPARA (0.58) PPARAPPARDPPARG
SCHEMBL5274267 0.94 PPARA (0.58) PPARAPPARDPPARG
SCHEMBL5579706 0.93 PPARA (0.52) PPARAPPARDPPARG
SCHEMBL5276156 0.92 PPARG (0.58) PPARAPPARDPPARG
SCHEMBL5271988 0.91 PPARG (0.57) PPARAPPARDPPARG
SCHEMBL5276379 0.91 PPARG (0.57) PPARAPPARDPPARG
SCHEMBL14366175 0.91 PPARA (0.60) PPARAPPARDPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7301033-B2 PPAR-activating compound KOWA CO., LTD. (JP) 2007-11-27 US disclosed
US-7301033-B2 PPAR-activating compound KOWA CO., LTD. (JP) 2007-11-27 US disclosed
US-7301033-B2 PPAR-activating compound KOWA CO., LTD. (JP) 2007-11-27 US disclosed
EP-1857447-A1 PPAR-ACTIVATING COMPOUND Kowa Company, Ltd. (JP) 2007-11-21 EP disclosed
US-20060167058-A1 PPAR-activating compound KOWA CO., LTD. (JP) 2006-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167058-A1 PPAR-activating compound PPARA, PPARG, PPARD PPARA 1/4885PPARD 3/4885PPARG 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.